Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa
暂无分享,去创建一个
[1] Patricia Tabernero,et al. Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database , 2014, Malaria Journal.
[2] M. Gharbi,et al. Trends in Antimalarial Drug Use in Africa , 2013, The American journal of tropical medicine and hygiene.
[3] L. Gostin,et al. Countering the Problem of Falsified and Substandard Drugs , 2013 .
[4] Justin M. Cohen,et al. Optimizing Investments in Malaria Treatment and Diagnosis , 2012, Science.
[5] Paul N Newton,et al. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. , 2012, The Lancet. Infectious diseases.
[6] P. Newton,et al. The WWARN Antimalarial Quality Surveyor , 2012, Pathogens and global health.
[7] Alan D. Lopez,et al. Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.
[8] Arantxa Roca-Feltrer,et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children , 2012, Nature Communications.
[9] P. Newton,et al. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority , 2011, Malaria Journal.
[10] P. Newton,et al. The Primacy of Public Health Considerations in Defining Poor Quality Medicines , 2011, PLoS Medicine.
[11] C. Goodman,et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries , 2011, Malaria Journal.
[12] C. Goodman,et al. The ACTwatch project: methods to describe anti-malarial markets in seven countries , 2011, Malaria Journal.
[13] Anne Mills,et al. Likely Health Outcomes for Untreated Acute Febrile Illness in the Tropics in Decision and Economic Models; A Delphi Survey , 2011, PloS one.
[14] N. Siva. Tackling the booming trade in counterfeit drugs , 2010, The Lancet.
[15] David L. Smith,et al. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty , 2010, Malaria Journal.
[16] P. Newton,et al. Impact of poor-quality medicines in the ‘developing’ world , 2010, Trends in pharmacological sciences.
[17] David A. Fidock,et al. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.
[18] R. Maude,et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance , 2009, Malaria Journal.
[19] P. Newton,et al. Guidelines for Field Surveys of the Quality of Medicines: A Proposal , 2009, PLoS medicine.
[20] N. White,et al. Qinghaosu (Artemisinin): The Price of Success , 2008, Science.
[21] P. Newton,et al. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. , 2008, The American journal of tropical medicine and hygiene.
[22] I. Okeke,et al. Antimicrobial resistance in developing countries , 1998, BMJ.
[23] Hadi Dowlatabadi,et al. Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .
[24] R. Cibulskis,et al. World Malaria Report 2013 , 2014 .
[25] P. Newton,et al. Counterfeit and Substandard Anti-infectives in Developing Countries , 2010 .
[26] Weltgesundheitsorganisation. World malaria report , 2005 .